Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Coherus Oncology (NASDAQ: CHRS) said senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 10:30 a.m. PT.
The presentation and Q&A will stream via webcast and a link will be posted on the company's Investor Events Calendar at https://investors.coherus.com/events-presentations. The webcast replay will be available through February 13, 2026.
Positive
- None.
Negative
- None.
News Market Reaction 21 Alerts
On the day this news was published, CHRS declined 5.56%, reflecting a notable negative market reaction. Argus tracked a peak move of +6.3% during that session. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $11M from the company's valuation, bringing the market cap to $185M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus 1 Down
CHRS gained 5.11% with strong volume, while key peers showed mixed moves: AGEN -1.23%, GLSI +7.56%, THTX +0.89%, TIL +7.90%, MCRB -0.72%. Momentum scanner flagged only TIL with a sharp move down 50.77%, suggesting CHRS trading was more stock-specific than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Clinical survival data | Positive | +6.7% | Reported six-year JUPITER-02 data showing markedly improved overall survival with LOQTORZI. |
| Nov 07 | Clinical biomarker update | Positive | -10.1% | Presented detailed CHS-114 biomarker and safety data in HNSCC at SITC 2025. |
| Nov 06 | Quarterly earnings | Negative | -4.8% | Released Q3 2025 results showing LOQTORZI-driven revenue growth but continued net loss. |
| Nov 06 | Leadership appointment | Positive | -4.8% | Announced new Chief Strategy and Corporate Affairs Officer to support oncology focus. |
| Oct 30 | Earnings scheduling | Neutral | -1.7% | Set date and webcast details for upcoming Q3 2025 financial results announcement. |
Recent news shows mixed alignment: strong positive clinical data and earnings updates sometimes produced selling pressure, while other clinical and informational releases aligned with price gains or modest declines.
Over the last few months, Coherus reported several key milestones. On Oct 30, 2025, it scheduled Q3 results and a business update for Nov 6. That day’s earnings release showed $11.6M in Q3 2025 revenue from continuing operations and a net loss of $(44.5M), coinciding with a -4.79% move. Also on Nov 6, the company added a Chief Strategy and Corporate Affairs Officer, again tied to a -4.79% reaction. Later, multiomic biomarker data for CHS-114 on Nov 7 saw a -10.07% move despite detailed positive immunologic activity. In contrast, six-year JUPITER-02 survival data for LOQTORZI on Dec 8 aligned with a +6.67% gain. Today’s conference participation fits within this backdrop of active clinical and corporate communication.
Regulatory & Risk Context
On Nov 13, 2025, Coherus filed a Form S-3 shelf to offer up to $150.0 million of mixed securities. The shelf replaces a prior registration, allows offerings via multiple channels, and has 0 recorded usages so far. This provides the company with flexibility to raise capital through equity, debt, or other securities via future prospectus supplements.
Market Pulse Summary
The stock moved -5.6% in the session following this news. A negative reaction despite a straightforward conference announcement would fit the mixed pattern seen in prior Coherus news, where even constructive updates sometimes preceded declines. With shares still about 23.81% below the 52-week high and an effective communication platform at the J.P. Morgan conference, attention could remain on financing flexibility from the $150.0 million shelf and on execution against previously disclosed clinical and financial milestones.
AI-generated analysis. Not financial advice.
REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Pacific Time. The presentation and Q&A session will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/events-presentations.
This webcast will be available for replay until February 13, 2026.
About Coherus Oncology
Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as through its partners, driving sales multiples and synergies from proprietary combinations.
Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.
For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com.
LOQTORZI® is a registered trademark of Coherus Oncology, Inc.
©2026 Coherus Oncology, Inc. All rights reserved.
Coherus Oncology Contact Information:
For Investors:
Carrie Graham
VP, Investor Relations & Advocacy
IR@coherus.com
FAQ
When will Coherus Oncology (CHRS) present at the J.P. Morgan Healthcare Conference?
How can investors watch the Coherus (CHRS) presentation on January 13, 2026?
Where is the Coherus (CHRS) webcast link for the J.P. Morgan presentation?
How long will the Coherus (CHRS) webcast replay be available?
Will Coherus (CHRS) include a Q&A during the J.P. Morgan presentation?
Is the Coherus (CHRS) presentation at J.P. Morgan open to the public online?
